Table 3.

ACR response criteria.

Study	Followup, Weeks	ACR20							ACR50							ACR70
		TT			Anti-TNF-α + MTX			p	TT		Anti-TNF-α + MTX				p	TT		Anti-TNF-α + MTX				p
		n	N	%	n	N	%	p	n	N	%	n	N	%	p	n	N	%	n	N	%	p
O’Dell, et al¹⁶ (RACAT)	24	89	159	56	90	163	55	0.89	41	159	25.8	58	163	35.6	0.06	8	159	5	26	163	16	0.001
van Vollenhoven, et al⁸ (SWEFOT)	48	37	130	28	54	128	42	0.03	19	130	15	32	128	25	0.04	9	130	7	15	128	12	0.20
Moreland, et al⁶ (TEAR) S	48–102	58	124	47	122	255	48	NS	46	124	37	82	255	32	NS	15	124	12	41	255	16	0.01
van Vollenhoven, et al¹⁸ (SWEFOT)	104	43	130	33	51	128	40	0.259	28	130	22	38	128	30	0.134	18	130	14	21	128	16	0.566

Significant data are in bold face. ACR20, 50, and 70: American College of Rheumatology 20%, 50%, 70% improvement, respectively; TT: triple oral combination therapy; anti-TNF-α: antitumor necrosis factor-α; MTX: methotrexate; n: no. participants with ACR20, 50, and 70 response; N: no. participants assessed; S: step-up treatment group; NS: not significant.